Retrospective Study of Clinical Effectiveness of Remdesivir in the Treatment of Moderate to Severe and critical Covid-19 Infections

Retrospective Study of Clinical Effectiveness of Remdesivir in the Treatment of Moderate to Severe and critical COVID-19 Infections

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20211109004

Enrollment

160

Registered

2021-11-09

Start date

2021-04-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clinical effectiveness of remdesivir in moderate to severe and critical COVID-19 Remdesivir

Interventions

Hospitalized patients with moderate to severe COVID-19 illness and received remdesivir for treatment,Hospitalized patients with critical COVID-19 illness and received remdesivir for treatment

Treatment,Treatment

Moderate to severe COVID-19 patients,Critical COVID-19 patients

Eligibility

Sex/Gender

All

Age

16 Years to No maximum

Inclusion criteria

Inclusion criteria: hospitalized patients with moderate to severe and critical COVID-19 illness and received remdesivir

Exclusion criteria

Exclusion criteria: mild COVID-19 illnes

Design outcomes

Primary

Measure	Time frame
clinical status at day 7 after treatment 7 days after treatment NEWS at day 7 after treatment	—

Secondary

Measure	Time frame
clinical status at day 14 after treatment 14 days after treatment NEWS at day 14 after treatment,30 days mortality 30 days after treatment mortality rate,length of stay within one year after treatment days	—

Countries

Thailand

Contacts

Public ContactRathakarn Kawila

Nakornping hospital

ticy_rk@yahoo.com66896374616

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026